JF Forbes

6.2k total citations · 2 hit papers
26 papers, 3.0k citations indexed

About

JF Forbes is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, JF Forbes has authored 26 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 14 papers in Oncology and 11 papers in Genetics. Recurrent topics in JF Forbes's work include Breast Cancer Treatment Studies (16 papers), Estrogen and related hormone effects (11 papers) and Advanced Breast Cancer Therapies (8 papers). JF Forbes is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), Estrogen and related hormone effects (11 papers) and Advanced Breast Cancer Therapies (8 papers). JF Forbes collaborates with scholars based in Australia, United Kingdom and United States. JF Forbes's co-authors include J Cuzick, Aman U. Budzar, J.G.M. Klijn, M Baum, Tarek Sahmoud, Joanna Houghton, Anthony Howell, Simon Cawthorn, AS Coates and Rob Edwards and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

JF Forbes

24 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

2002 1.5k citations M Baum, Aman U. Budzar et al. The Lancet profile →
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial

2002 533 citations J Cuzick, JF Forbes et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
JF Forbes Australia	12	1.9k	1.7k	1.4k	471	343	26	3.0k
Simon Cawthorn United Kingdom	23	1.5k 0.8×	1.7k 1.0×	1.3k 1.0×	495 1.1×	305 0.9×	54	3.6k
M Baum United Kingdom	11	2.4k 1.2×	2.0k 1.2×	1.6k 1.2×	573 1.2×	455 1.3×	34	3.6k
G Hoctin-Boes Netherlands	8	1.5k 0.8×	1.4k 0.8×	958 0.7×	392 0.8×	278 0.8×	12	2.4k
Monica Castiglione Switzerland	17	1.3k 0.7×	1.4k 0.9×	1.3k 1.0×	522 1.1×	258 0.8×	26	2.4k
J. Houghton United Kingdom	19	1.8k 0.9×	2.2k 1.3×	2.2k 1.6×	644 1.4×	395 1.2×	51	4.1k
A. Buzdar United States	7	1.2k 0.6×	1.2k 0.7×	846 0.6×	356 0.8×	253 0.7×	16	2.0k
J S Tobias United Kingdom	11	1.1k 0.6×	1.3k 0.8×	715 0.5×	402 0.9×	291 0.8×	16	2.3k
Gun Anker Norway	22	1.2k 0.6×	1.3k 0.8×	914 0.7×	396 0.8×	536 1.6×	38	2.4k
Alwynne Tidy United Kingdom	11	1.2k 0.6×	1.5k 0.9×	604 0.4×	284 0.6×	302 0.9×	17	2.2k
Reena S. Cecchini United States	20	1.1k 0.5×	1.8k 1.1×	959 0.7×	422 0.9×	393 1.1×	49	2.9k

Countries citing papers authored by JF Forbes

Since Specialization

Citations

This map shows the geographic impact of JF Forbes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JF Forbes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JF Forbes more than expected).

Fields of papers citing papers by JF Forbes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JF Forbes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JF Forbes. The network helps show where JF Forbes may publish in the future.

Co-authorship network of co-authors of JF Forbes

This figure shows the co-authorship network connecting the top 25 collaborators of JF Forbes. A scholar is included among the top collaborators of JF Forbes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JF Forbes. JF Forbes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gray, Kathryn P., Meinir Krishnasamy, Meredith M. Regan, et al.. (2019). Abstract OT2-04-03: Examining personalized radiation therapy (EXPERT): A randomised phase III trial of adjuvant radiotherapy vs observation in patients with molecularly characterized luminal A breast cancer. Cancer Research. 79(4_Supplement). OT2–4. 4 indexed citations

Kolovos, Spyros, et al.. (2017). Discrete Event Simulation Modelling of Long Term Cost-Effectiveness of Internet-Based Blended Cognitive Behavioural Therapy for Major Depressive Disorder: Extrapolation of the E-Compared Randomised Controlled Trial. Value in Health. 20(9). A403–A403.

Thorat, Mangesh A., Rani A. Hoff, Zaina Sangale, et al.. (2017). Abstract P1-09-06: Prognostic and predictive relevance of cell cycle progression (CCP) score in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial. Cancer Research. 77(4_Supplement). P1–9. 1 indexed citations

McCarthy, Nicole, Frances Boyle, Nicholas Zdenkowski, et al.. (2014). Neoadjuvant chemotherapy with sequential anthracycline–docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem). The Breast. 23(2). 142–151. 5 indexed citations

Huober, Jens, Bernard F. Cole, Manuela Rabaglio, et al.. (2013). Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Research and Treatment. 143(1). 159–169. 33 indexed citations

Viale, Giuseppe, MM Regan, Patrizia Dell’Orto, et al.. (2011). Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Annals of Oncology. 22(10). 2201–2207. 65 indexed citations

Šestak, Ivana, J. Cuzick, Mitch Dowsett, et al.. (2011). P2-12-09: Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study.. Cancer Research. 71(24_Supplement). P2–12. 1 indexed citations

Huober, J., Jian Wu, Anita Giobbie‐Hurder, et al.. (2011). Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial.. Journal of Clinical Oncology. 29(15_suppl). 522–522. 6 indexed citations

Rabaglio, Manuela, Zijie Sun, Karen N. Price, et al.. (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology. 20(9). 1489–1498. 133 indexed citations

10.

Dowsett, Mitch, J Cuzick, Craig Wales, et al.. (2009). Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.. Cancer Research. 69(2_Supplement). 53–53. 25 indexed citations

11.

Bliss, Judith M., Lucy Kilburn, Robert E. Coleman, et al.. (2009). Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES).. Cancer Research. 69(24_Supplement). 12–12. 10 indexed citations

12.

Juraskova, Ilona, Phyllis Butow, Alan S. Coates, et al.. (2008). Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS‐II DCIS). Health Expectations. 11(3). 252–262. 50 indexed citations

13.

Cuzick, Jack, JF Forbes, Ivana Šestak, et al.. (2007). Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. JNCI Journal of the National Cancer Institute. 99(4). 272–282. 371 indexed citations

14.

Mauriac, L., Aparna Keshaviah, M. Debled, et al.. (2006). Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. European Journal of Cancer Supplements. 4(2). 111–111. 10 indexed citations

15.

Baum, M, Aman U. Budzar, J Cuzick, et al.. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. The Lancet. 359(9324). 2131–2139. 1461 indexed citations breakdown →

16.

Cuzick, J, JF Forbes, Rob Edwards, et al.. (2002). First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet. 360(9336). 817–824. 533 indexed citations breakdown →

17.

Johnstone, Elaine, et al.. (1997). Service provision for people with schizophrenia. The British Journal of Psychiatry. 171(2). 159–164. 38 indexed citations

18.

Hürny, Christoph, Jürg Bernhard, Monica Castiglione‐Gertsch, et al.. (1996). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. The Lancet. 347(9011). 1279–1284. 147 indexed citations

19.

Jonat, W., M. Kaufmann, R.W. Blamey, et al.. (1993). Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only. The Breast. 2(3). 203–204. 2 indexed citations

20.

Anıl, Murat & JF Forbes. (1980). Effects of Insulin and Gastro-Intestinal Hormones on Feeding and Plasma Insulin Levels in Sheep. Hormone and Metabolic Research. 12(6). 234–236. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact